<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pone.0227532.t001" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1371/journal.pone.0227532.t001</object-id>
 <label>Table 1</label>
 <caption>
  <title>Characteristics of the included trials.</title>
 </caption>
 <alternatives>
  <graphic id="pone.0227532.t001g" xlink:href="pone.0227532.t001" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="left" rowspan="1" colspan="1">Study</th>
     <th align="left" rowspan="1" colspan="1">Year</th>
     <th align="left" rowspan="1" colspan="1">Region</th>
     <th align="justify" rowspan="1" colspan="1">Study design</th>
     <th align="justify" rowspan="1" colspan="1">Mean age (y)</th>
     <th align="justify" rowspan="1" colspan="1">Sex</th>
     <th align="justify" rowspan="1" colspan="1">Intervention</th>
     <th align="justify" rowspan="1" colspan="1">Control</th>
     <th align="justify" rowspan="1" colspan="1">Duration</th>
     <th align="justify" rowspan="1" colspan="1">Follow-up</th>
     <th align="justify" rowspan="1" colspan="1">Dropo
      <break/>ut
     </th>
     <th align="justify" rowspan="1" colspan="1">Outcomes</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td align="left" rowspan="1" colspan="1">Sun et al[
      <xref rid="pone.0227532.ref017" ref-type="bibr">17</xref>]
     </td>
     <td align="left" rowspan="1" colspan="1">2017</td>
     <td align="left" rowspan="1" colspan="1">Shanghai</td>
     <td align="left" rowspan="1" colspan="1">CCT</td>
     <td align="left" rowspan="1" colspan="1">42.8±13.2</td>
     <td align="left" rowspan="1" colspan="1">M:28 F:10</td>
     <td align="left" rowspan="1" colspan="1">LAM (100 mg/day
      <break/>orally)+ACEI/ARB (n = 20)
     </td>
     <td align="left" rowspan="1" colspan="1">ACEI/ARB alone (n = 18)</td>
     <td align="left" rowspan="1" colspan="1">12 mo</td>
     <td align="left" rowspan="1" colspan="1">12 mo</td>
     <td align="left" rowspan="1" colspan="1">0</td>
     <td align="left" rowspan="1" colspan="1">①②</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Bhimma et al[
      <xref rid="pone.0227532.ref018" ref-type="bibr">18</xref>]
     </td>
     <td align="left" rowspan="1" colspan="1">2002</td>
     <td align="left" rowspan="1" colspan="1">Durban, South Africa</td>
     <td align="left" rowspan="1" colspan="1">CCT</td>
     <td align="left" rowspan="1" colspan="1">8.9</td>
     <td align="left" rowspan="1" colspan="1">M:34 F:5</td>
     <td align="left" rowspan="1" colspan="1">IFN-α2b (10 million units/m2 3 times/week)(n = 19)</td>
     <td align="left" rowspan="1" colspan="1">control of edema and hypertension (n = 20)</td>
     <td align="left" rowspan="1" colspan="1">16 weeks</td>
     <td align="left" rowspan="1" colspan="1">40 weeks</td>
     <td align="left" rowspan="1" colspan="1">5</td>
     <td align="left" rowspan="1" colspan="1">①②③</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Tang et al[
      <xref rid="pone.0227532.ref019" ref-type="bibr">19</xref>]
     </td>
     <td align="left" rowspan="1" colspan="1">2005</td>
     <td align="left" rowspan="1" colspan="1">Hong Kong, China</td>
     <td align="left" rowspan="1" colspan="1">CCT</td>
     <td align="left" rowspan="1" colspan="1">45.5±19.0</td>
     <td align="left" rowspan="1" colspan="1">M:14 F:8</td>
     <td align="left" rowspan="1" colspan="1">LAM 100mg/d+ACEI or ARB (n = 10)</td>
     <td align="left" rowspan="1" colspan="1">ACEI/ARB (n = 12)</td>
     <td align="left" rowspan="1" colspan="1">NA</td>
     <td align="left" rowspan="1" colspan="1">49.2±16.5 mo</td>
     <td align="left" rowspan="1" colspan="1">0</td>
     <td align="left" rowspan="1" colspan="1">①③</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Panomsak et al[
      <xref rid="pone.0227532.ref020" ref-type="bibr">20</xref>]
     </td>
     <td align="left" rowspan="1" colspan="1">2006</td>
     <td align="left" rowspan="1" colspan="1">Thailand</td>
     <td align="left" rowspan="1" colspan="1">CCT</td>
     <td align="left" rowspan="1" colspan="1">40.9</td>
     <td align="left" rowspan="1" colspan="1">M:10 F:7</td>
     <td align="left" rowspan="1" colspan="1">1 month of prednisone, then 6 had LAM and 1 had IFN-α (n = 7)</td>
     <td align="left" rowspan="1" colspan="1">ACEI, fish oil, or neither (n = 10)</td>
     <td align="left" rowspan="1" colspan="1">NA</td>
     <td align="left" rowspan="1" colspan="1">5–120 mo</td>
     <td align="left" rowspan="1" colspan="1">3</td>
     <td align="left" rowspan="1" colspan="1">①</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Sun et al[
      <xref rid="pone.0227532.ref021" ref-type="bibr">21</xref>]
     </td>
     <td align="left" rowspan="1" colspan="1">2012</td>
     <td align="left" rowspan="1" colspan="1">Seoul, Korea</td>
     <td align="left" rowspan="1" colspan="1">CCT</td>
     <td align="left" rowspan="1" colspan="1">37</td>
     <td align="left" rowspan="1" colspan="1">M:9 F:1</td>
     <td align="left" rowspan="1" colspan="1">Antiviral drugs (n = 6)</td>
     <td align="left" rowspan="1" colspan="1">ACEI or ARB (n = 4)</td>
     <td align="left" rowspan="1" colspan="1">NA</td>
     <td align="left" rowspan="1" colspan="1">mean 87 mo (8–187)</td>
     <td align="left" rowspan="1" colspan="1">1</td>
     <td align="left" rowspan="1" colspan="1">①</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Lai et al[
      <xref rid="pone.0227532.ref022" ref-type="bibr">22</xref>]
     </td>
     <td align="left" rowspan="1" colspan="1">1991</td>
     <td align="left" rowspan="1" colspan="1">Hong Kong, China</td>
     <td align="left" rowspan="1" colspan="1">CCT</td>
     <td align="left" rowspan="1" colspan="1">30</td>
     <td align="left" rowspan="1" colspan="1">M:14 F:2</td>
     <td align="left" rowspan="1" colspan="1">IFN-α2b (3 million units, 3 times/week, subcutaneous injection)(n = 5)</td>
     <td align="left" rowspan="1" colspan="1">diuretic agents/dipyridamole /no treatment (n = 11)</td>
     <td align="left" rowspan="1" colspan="1">12 weeks</td>
     <td align="left" rowspan="1" colspan="1">55.1 mo</td>
     <td align="left" rowspan="1" colspan="1">0</td>
     <td align="left" rowspan="1" colspan="1">①②③</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Lin et al[
      <xref rid="pone.0227532.ref023" ref-type="bibr">23</xref>]
     </td>
     <td align="left" rowspan="1" colspan="1">1995</td>
     <td align="left" rowspan="1" colspan="1">Taiwan, China</td>
     <td align="left" rowspan="1" colspan="1">RCT</td>
     <td align="left" rowspan="1" colspan="1">6.5±3.3</td>
     <td align="left" rowspan="1" colspan="1">M:29 F:11</td>
     <td align="left" rowspan="1" colspan="1">IFN-α2b (5μ if body weight&lt;20 kg, 8μ if body weight&gt;20 kg, 3 times/week subcutaneous injection)</td>
     <td align="left" rowspan="1" colspan="1">control
      <break/>of edema and hypertension
     </td>
     <td align="left" rowspan="1" colspan="1">12 mo</td>
     <td align="left" rowspan="1" colspan="1">24 mo</td>
     <td align="left" rowspan="1" colspan="1">0</td>
     <td align="left" rowspan="1" colspan="1">③</td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="t001fn001">
   <p>Abbreviations: RCT, randomized controlled trial; CCT, cohort clinical trial; M, male; F, female; LAM, lamivudine; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; NA, not available; mo, months; ①Renal remission; ②eGFR (estimated glomerular filtration rate); ③HBeAg clearance.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
